DOI: https://doi.org/10.22263/2312-4156.2017.5.40
Chekalina N.I., Manusha Y.I.
The expediency substantiation of the resveratrol and quercetin polyphenols use in ischemic heart disease combined with autoimmune thyroiditis. Part I
Ukrainian Medical Stomatological Academy, Poltava, Ukraine
Vestnik VGMU. 2017;16(5):40-48.
Abstract.
This review presents modern scientific conceptions concerning the mechanisms of the formation and progression of atherosclerosis - the morphological basis of coronary heart disease (CHD) - and autoimmune thyroiditis in terms of the inflammatory theory, recognized as the leading one in the pathogenesis of the above diseases. The inflammatory mechanisms realized at the epigenetic, molecular, cellular levels, their community and universality in the development of both pathologies are described. The role of polyphenolic compounds as powerful anti-inflammatory agents is shown.
The main mechanisms of anti-inflammatory activity of resveratrol and quercetin are specified, which proves the expediency of their use in the complex treatment of diseases, in the development of which the leading role is played by chronic systemic inflammation.
Key words: ischemic heart disease, atherosclerosis, autoimmune thyroiditis, chronic systemic inflammation, resveratrol, quercetin.
References
1. Townsend N, Wilson L, Bhatnagar P, Wickramasinghe K, Rayner M, Nichols M. Cardiovascular disease in Europe 2016: epidemiological update. Eur Heart J. 2016 Nov;37(42):3232-3245. doi: http://dx.doi.org/10.1093/eurheartj/ehw334
2. Vanderpump MP. The epidemiology of thyroid disease. Br Med Bull. 2011;99:39-51. doi: http://dx.doi.org/10.1093/bmb/ldr030
3. Levina LI, Kapitonova NV. Autoimmune lesion of a myocardium at young women with a diffuse nontoxic struma and an autoimmune thyroiditis. V: Endokrinnaia patologiia i serdechno-sosudistaia sistema: problemy, zadachi, puti resheniia: nauchn-prakt konf Severo-Zapad regiona RF 26–27 apr 2007 Sankt-Peterburg: materialy konf. Saint Petersburg, RF; 2007. З. 34. (In Russ.)
4. Mazziotti G, Sorvillo F, Naclerio C, Farzati A, Cioffi M, Perna R, et al. Type-1 response in peripheral CD4+ and CD8+ T cells from patients with Hashimoto’s thyroiditis. Eur J Endocrinol. 2003 Apr;148(4):383-8.
5. Dusi V, Ghidoni A, Ravera A, De Ferrari GM, Calvillo L. Chemokines and Heart Disease: A Network Connecting Cardiovascular Biology to Immune and Autonomic Nervous Systems. Mediat Inflamm. 2016;2016. doi: http://dx.doi.org/10.1155/2016/5902947
6. Charnotska B. Thyroid peroxidase: enzyme and antigen [Elektronnyi resurs]. Mezhdunar Endokrinol Zhurn. 2007;3(9). Rezhim dostupa: http://www.mif-ua.com/archive/article/451. Data dostupa: 09.10.2017.
7. Shimuzu N. Lipid mediators in health and disease: enzymes and receptors as therapeutic targets for the regulation of immunity and inflammation. Annu Rev Pharmacol Toxicol. 2009;49:123-50. doi: http://dx.doi.org/10.1146/annurev.pharmtox.011008.145616
8. Shi Y, Wang H, Su Z, Chen J, Xue Y, Wang S, et al. Differentiation imbalance of Th1/Th17 in peripheral blood mononuclear cells might contribute to pathogenesis of Hashimoto's thyroiditis. Scand J Immunol. 2010 Sep;72(3):250-5. doi: http://dx.doi.org/10.1111/j.1365-3083.2010.02425.x
9. Mallat Z, Gojova A, Brun V, Esposito B, Fournier N, Cottrez F, Tedgui A, et al. Induction of a regulatory T cell type 1 response reduces the development of atherosclerosis in apolipoprotein E-knockout mice. Circulation. 2003 Sep;108(10):1232-7. doi: http://dx.doi.org/10.1161/01.CIR.0000089083.61317.A1
10. Kukhtina NB, Aref'yeva TI, Aref'yeva AM, Akchurin RS, Krasnikova TL. Expression of chemokines and cytokines in atherosclerotic plaques and an internal cover of arteries at ischemic heart disease patients. Terapevt Arkh. 2008;80(4):63-69. (In Russ.)
11. Hasham A, Tome Y. Genetic and epigenetic mechanisms in thyroid autoimmunity. Immunol Res. 2012 Dec;54(1-3)6:204-13. doi: http://dx.doi.org/10.1007/s12026-012-8302-x
12. Kaydashev IP. NF-kB role in functioning of separate tissues, development and a sintropiya of diseases of the main systems of an organism. Zhurn Nats Akad Med nauk Ukraїni. 2012;18(2):186-98.(In Russ.)
13. Ganesh BB, Bhattacharya P, Gopisetty A, Prabhakar BS. Role of cytokines in the pathogenesis and suppression of thyroid autoimmunity. J Interferon Cytokine Res. 2011 Oct;31(10):721-31. doi: http://dx.doi.org/10.1089/jir.2011.0049
14. Wang SH, Bretz JD, Phelps E, Mezosi E, Arscott PL, Utsugi S, et al. A unique combination of inflammatory cytokines enhances apoptosis of thyroid follicular cells and transforms nondestructive to destructive thyroiditis in experimental autoimmune thyroiditis. J Immunol. 2002 Mar;168(5):2470-4.
15. Tanigaki K, Sundgren N, Khera A, Vongpatanasin W, Mineo C, Shaul PW. Fcγ Receptors and Ligands and Cardiovascular Disease. Circ Res. 2015 Jan;116(2):368-84. doi: http://dx.doi.org/10.1161/CIRCRESAHA.116.302795
16. Xi D, Zhao J, Lai W, Guo Z. Systematic analysis of the molecular mechanism underlying atherosclerosis using a text mining approach. Hum Genomics. 2016;10:14. doi: http://dx.doi.org/10.1186/s40246-016-0075-1
17. Mester T, Raychaudhuri N, Gillespie EF, Chen H, Smith TJ, Douglas RS. CD40 expression in fibrocytes is induced by TSH: Potential synergistic immune activation. PLoS One [Internet]. 2016 Sep [cited 2017 Oct 09];11(9):e0162994. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5025085/.
18. Wagner AH, Gebauer M, Pollok-Kopp B, Hecker M. Cytokine-inducible CD40 expression in human endothelial cells is mediated by interferon regulatory factor-1. Blood. 2002 Jan;99(2):520-5.
19. Peters AL, Stunz LL, Bishop GA. CD40 and autoimmunity: The dark side of a great activator. Semin Immunol. 2009 Oct;21(5):293-300. doi: http://dx.doi.org/10.1016/j.smim.2009.05.012
20. Vinayagamoorthi R, Bidhan Chandra Koner, Kavitha S, Nandakumar DN, Padma Priya P, Kalyan Goswami. Potentiation of humoral immune response and activation of NF-kappaB pathway in lymphocytes in experimentally induced hyperthyroid rats. Cell Immunol. 2005 Nov;238(1):5-60. doi: http://dx.doi.org/10.1016/j.cellimm.2006.01.002
21. Yoon JH, Baek SJ. Molecular targets of dietary polyphenols with antiinflammatory properties. Yonsei Med J. 2005 Oct;46(5):585-96. doi: http://dx.doi.org/10.3349/ymj.2005.46.5.585
22. Andriantsitohaina R, Auger C, Chataigneau T, Étienne-Selloum N, Li H, Martínez MC, et al. Molecular mechanisms of the cardiovascular protective effects of polyphenols. Br J Nutr. 2012 Nov;108(9):1532-49. doi: http://dx.doi.org/10.1017/S0007114512003406
23. Zalesskiy VN, Velikaya NV, Omel'chuk ST. Antiinflammatory delivery in prophylaxis and treatment noninfectious (including tumoral) diseases of the person. Molecular protective mechanisms of bioactive components of a nutrition: monografiia. Vinnitsa, Ukraine: Nova Kniga; 2014. 736 р. (In Russ.)
24. Calabriso N, Scoditti E, Massaro M, Pellegrino M, Storelli C, Ingrosso I, et al. Multiple anti-inflammatory and anti-atherosclerotic properties of red wine polyphenolic extracts: differential role of hydroxycinnamic acids, flavonols and stilbenes on endothelial inflammatory gene expression. Eur J Nutr. 2016 Mar;55(2):477-489. doi: http://dx.doi.org/10.1007/s00394-015-0865-6
25. Yang T, Wang L, Zhu M, Zhang L, Yan L. Properties and molecular mechanisms of resveratrol: a review. Pharmazie. 2015 Aug;70(8):501-6.
26. Mamchur VY, Markhon' NO. Farmakologіchna kharakteristika resveratrolu. Farmakologіia Lіkar Toksikologіia. 2012;(4):3-9. (In Ukr.)
27. Takaoka M. Resveratrol, a new phenolic compound from Veratrum grandiflorum. J Chem Soc Japan. 1939;60:1090-100.
28. Ramprasath VR, Jones PJ. Anti-atherogenic effects of resveratrol. Eur J Clin Nutr. 2010 Jul;64(7):660-8. doi: http://dx.doi.org/10.1038/ejcn.2010.77
29. Poulsen MM, Fjeldborg K, Ornstrup MJ, Kjær TN, Nøhr MK, Pedersen SB. Resveratrol and inflammation: Challenges in translating pre-clinical findings to improved patient outcomes. Biochim Biophys Acta. 2015 Jun;1852(6):1124-36. doi: http://dx.doi.org/10.1016/j.bbadis.2014.12.024
30. Ren Z, Wang L, Cui J, Huoc Z, Xue J, Cui H, et al. Resveratrol inhibits NF-kB signaling through suppression of p65 and IkappaB kinase activities. Pharmazie. 2013 Aug;68(8):689-94.
31. Voytenko GN, Shalamay AS, Luk'yanchuk VD, Stepanenko VV, Mamchur VI, Maslova NF, i dr. Pharmakoterapevtichesky properties of drugs of Quercetinum. Farmakologіia Lіkar Toksikologіia. 2011;(5):55-7. (In Russ.)
32. Moybenko AA, red. Bioflavonoids as organoprotection: quercetin, corvitin, quartin. Kiev, Ukraine: Naukova dumka; 2012. 274 р. (In Russ.)
33. Miles SL, McFarland M, Niles RM. Molecular and physiological actions of quercetin: need for clinical trials to assess its benefits in human disease. Nutr Rev. 2014 Nov;72(11):720-34. doi: http://dx.doi.org/10.1111/nure.12152
34. Li Y, Yao J, Han C, Yang J, Chaudhry MT, Wang S, et al. Quercetin, inflammation and immunity. Nutrients. 2016 Mar;8(3):167. doi: http://dx.doi.org/10.3390/nu8030167
35. Tomé-Carneiro J, Gonzálvez M, Larrosa M, García-Almagro FJ, Avilés-Plaza F, Parra S, et al. Consumption of a grape extract supplement containing resveratrol decreases oxidized LDL and ApoB in patients undergoing primary prevention of cardiovascular disease: a triple-blind, 6-month follow-up, placebo-controlled, randomized trial. Mol Nutr Food Res. 2012 May;56(5):810-21. doi: http://dx.doi.org/10.1002/mnfr.201100673
36. de Lorgeril M, Salen P, Martin JL, Monjaud I, Delaye J, Mamelle N. Mediterranean diet, traditional risk factors, and the rate of cardiovascular complications after myocardial infarction: final report of the Lyon Diet Heart Study. Circulation. 1999 Feb;99(6):779-85.
37. Smoliga JM, Baur JA, Hausenblas HA. Resveratrol and health – a comprehensive review of human clinical trials. Mol Nutr Food Res. 2011 Aug;55(8):1129-41. doi: http://dx.doi.org/10.1002/mnfr.201100143
38. Militaru C, Donoiu I, Craciun A, Scorei ID, Bulearca AM, Scorei RI. Oral resveratrol and calcium fructoborate supplementation in subjects with stable angina pectoris: effects on lipid profiles, inflammation markers, and quality of life. Nutrition. 2013 Jan;29(1):178-83. doi: http://dx.doi.org/10.1016/j.nut.2012.07.006
39. Tomé-Carneiro J, Gonzálvez M, Larrosa M, Yáñez-Gascón MJ, García-Almagro FJ, Ruiz-Ros JA, et al. Grape resveratrol increases serum adiponectin and downregulates inflammatory genes in peripheral blood mononuclear cells: a triple-blind, placebo-controlled, one-year clinical trial in patients with stable coronary artery disease. Cardiovasc Drugs Ther. 2013 Feb;27(1):37-48. doi: http://dx.doi.org/10.1007/s10557-012-6427-8
40. Tomé-Carneiro J, Gonzálvez M, Larrosa M, García-Almagro FJ, Avilés-Plaza F, Parra S, et al. Consumption of a grape extract supplement containing resveratrol decreases oxidized LDL and ApoB in patients undergoing primary prevention of cardiovascular disease: a triple-blind, 6-month follow-up, placebo-controlled, randomized trial. Mol Nutr Food Res. 2012 May;56(5):810-21. doi: http://dx.doi.org/10.1002/mnfr.201100673
41. Tomé-Carneiro J, Gonzálvez M, Larrosa M, Yáñez-Gascón MJ, García-Almagro FJ, Ruiz-Ros JA, et al. One-year consumption of a grape nutraceutical containing resveratrol improves the inflammatory and fibrinolytic status of patients in primary prevention of cardiovascular disease. Am J Cardiol. 2012 Aug;110(3):356-63. doi: http://dx.doi.org/10.1016/j.amjcard.2012.03.030
42. Tomé-Carneiro J, Larrosa M, Yáñez-Gascón MJ, Dávalos A, Gil-Zamorano J, Gonzálvez M, et al. One-year supplementation with a grape extract containing resveratrol modulates inflammatory-related microRNAs and cytokines expression in peripheral blood mononuclear cells of type 2 diabetes and hypertensive patients with coronary artery disease. Pharmacol Res. 2013 Jun;72:69-82. doi: http://dx.doi.org/10.1016/j.phrs.2013.03.011
43. Rossi R, Nuzzo A, Origliani G, Modena MG. Prognostic role of flow-mediated dilation and cardiac risk factors in post-menopausal women. J Am Coll Cardiol. 2008 Mar;51(10):997-1002. doi: http://dx.doi.org/10.1016/j.jacc.2007.11.044
44. Zordoky BN, Robertson IM, Dyck JR2. Preclinical and clinical evidence for the role of resveratrol in the treatment of cardiovascular diseases. Biochim Biophys Acta. 2015 Jun;1852(6):1155-77. doi: http://dx.doi.org/10.1016/j.bbadis.2014.10.016
45. Wang B, Sun J, Li X, Zhou Q, Bai J, Shi Y, et al. Resveratrol prevents suppression of regulatory T-cell production, oxidative stress, and inflammation of mice prone or resistant to high-fat diet-induced obesity. Nutr Res. 2013 Nov;33(11):971-81. doi: http://dx.doi.org/10.1016/j.nutres.2013.07.016
46. Ungvari Z, Sonntag WE, de Cabo R, Baur JA, Csiszar A. Mitochondrial protection by resveratrol. Exerc Sport Sci Rev. 2011 Jul;39(3):128-32. doi: http://dx.doi.org/10.1097/JES.0b013e3182141f80
47. Agarwal B, Campen MJ, Channell MM, Wherry SJ, Varamini B, Davis JG, et al. Resveratrol for primary prevention of atherosclerosis: Clinical trial evidence for improved gene expression in vascular endothelium. Int J Cardiol. 2013 Jun;166(1):246-8. doi: http://dx.doi.org/10.1016/j.ijcard.2012.09.027
48. de Oliveira MR, Nabavi SM, Braidy N, Setzer WN, Ahmed T, Nabavi SF. Quercetin and the mitochondria: A mechanistic view. Biotechnol Adv. 2016 Sep-Oct;34(5):532-549. doi: http://dx.doi.org/10.1016/j.biotechadv.2015.12.014
49. Hertog MG, Feskens EJ, Hollman PC, Katan MB, Kromhout D. Dietary antioxidant flavonoids and risk of coronary heart disease: the Zutphen Elderly Study. Lancet. 1993 Oct;342(8878):1007-11.
50. Huxley RR, Neil HA. The relation between dietary flavonol intake and coronary heart disease mortality: a meta-analysis of prospective cohort studies. Eur J Clin Nutr. 2003 Aug;57(8):904-8.
51. Wang ZM, Nie ZL, Zhou B, Lian XQ, Zhao H, Gao W, et al. Flavonols intake and the risk of coronary heart disease: a meta-analysis of cohort studies. Atherosclerosis. 2012 May;222(1):270-3. doi: http://dx.doi.org/10.1016/j.atherosclerosis.2012.02.026
52. Wang ZM,Zhao D, Nie ZL, Zhao H, Zhou B, Gao W, et al. Flavonol intake and stroke risk: a meta-analysis of cohort studies. Nutrition. 2014 May;30(5):518-23. doi: http://dx.doi.org/10.1016/j.nut.2013.10.009
53. Parkhomenko AN, Kozhukhov SN. Efficiency of an intravenous form of a blocker 5 lipoxygenases of Quercetinum at patients with a myocardial infarction and a syndrome of an acute heart failure: possible connection with correction of a metabolism of nitrogen oxide. Ukr Med Chasopis. 2005;(2):45-51. (In Russ.)
54. Parkhomenko AN, Kozhukhov SN. Results of open randomized study on studying of an acceptability and efficiency of the drug Korvitin at patients with a congestive heart failure and systolic dysfunction of a left ventricle. Ukr Med Chasopis. 2014;(4):71-6. (In Russ.)
55. Loke WM, Hodgson JM, Proudfoot JM, McKinley AJ, Puddey IB, Croft KD. Pure dietary flavonoids quercetin and epicatechin augment nitric oxide products and reduce endothelin-1 acutely in healthy men. Am J Clin Nutr. 2008 Oct;88(4):1018-25.
56. Perez-Vizcaino F, Duarte J, Jimenez R, Santos-Buelga C, Osuna A. Antihypertensive effects of the flavonoid quercetin. Pharmacol Rep. 2009 Jan-Feb;61(1):67-75.
57. Periasamy R, Kalal IG, Krishnaswamy R, Viswanadha V. Quercetin protects human peripheral blood mononuclear cells from OTA-induced oxidative stress, genotoxicity, and inflammation. Environ Toxicol. 2016 Jul;31(7):855-65. doi: http://dx.doi.org/10.1002/tox.22096
58. Scientific Opinion on the substantiation of health claims related to quercetin and protection of DNA, proteins and lipids from oxidative damage (ID 1647), «cardiovascular system» (ID 1844), «mental state and performance» (ID 1845), and «liver, kidneys» (ID 1846) pursuant to Article 13(1) of Regulation (EC) No 1924/2006. EFSA J. 2011 Apr;9(4):2067-82. doi: http://dx.doi.org/10.2903/j.efsa.2011.2067
Information about authors:
Chekalina N.I. – Candidate of Medical Sciences, associate professor of the Chair of Propedeutics of Internal Medicine with Patients Care, General Practice (Family Medicine), Ukrainian Medical Stomatological Academy;
Manusha Y.I. – postgraduate of the Chair of Internal Medicine with Patients Care, General Practice (Family Medicine), Ukrainian Medical Stomatological Academy.
Correspondence address: Ukraine, 36000, Poltava, 23 Shevchenko str., Ukrainian Medical Stomatological Academy, Chair of Propedeutics of Internal Medicine with Patients Care, General Practice (Family Medicine). E-mail: Этот адрес электронной почты защищён от спам-ботов. У вас должен быть включен JavaScript для просмотра. – Natalya I. Chekalina.
